More than one in seven adults in the U.S. are estimated to have chronic kidney disease, but most people don’t know they have it. Startup Monogram Health is looking to change this by helping people identify chronic kidney disease sooner and giving them access to clinicians to help slow its progression.
The Nashville, Tenn.-based company was co-founded just two years ago by Michael Uchrin, a former insurance executive with health choice. It recently raised $160 million in a series B funding round led by TPG Capital.
Many patients face barriers to accessing care in the current system. The U.S. currently has just 8,000 nephrologists to treat more than 30 million people with kidney disease. On top of that, many patients don’t experience symptoms until kidney disease is very late stage, either going undiagnosed or delaying care because they feel fine.
Monogram’s goal is to prevent the progression of kidney disease, and to better inform patients about their options, the company wrote in an emailed statement.
The startup offers in-home support to patients with chronic kidney disease or end-stage renal disease. Patients are paired with a registered nurse care manager and a social worker, under the leadership of a nephrologist.
It also claims its AI technology can proactively identify members at risk of progression from chronic kidney disease.
“Despite more than 20 percent of all Medicare spending going toward Americans with kidney disease, the population continues to grow and experience often dismal health outcomes and quality of life,” Uchrin said in a news release. “Our model of care dramatically improves health outcomes and reduces spending by delivering the care and services these individuals truly need and want, right in their own homes.”
Earlier this year, the company struck a partnership with Humana to help coordinate care for its Medicare Advantage and commercial members in four states.
With the new funding, TPG Capital Co-Managing Partner Todd Sisitsky will join Monogram’s board of directors.
“As someone who has supported a family member through end?stage renal disease, I witnessed first?hand the challenges and deficiencies that Monogram is addressing,” he said in a news release. “I couldn’t be more optimistic about the future of the company and the lives it’s changing every day.”
Humana and Frist Cressey Ventures, a fund started by former U.S. senator Bill Frist, also participated in the round (Frist is chairman of the company). Former CMS Administrator Seema Verma also joined the company’s board earlier this year.
With the new funding, Monogram plans to further its expansion across the U.S.
Photo credit: HYWARDS, Getty Images
Correction: This article has been updated to reflect that this is Humana’s first investment in Monogram Health.